2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-117777
    GSK121 1652591-80-4 99.81%
    GSK-121 Trifluoroacetates a selective PAD4 inhibitor.
    GSK121
  • HY-120657
    9-PAHSA 1481636-31-0 99.88%
    9-PAHSA is an orally available anti-inflammatory lipid that lowers blood sugar and reduces inflammation. 9-PAHSA also improved carotid vascular calcification and attenuates cardiac hypertrophy and dysfunction in db/db mice. 9-PAHSA increases the viability of steatosis primary mouse hepatocytes (PMH). 9-PAHSA can be used in research on diabetes, inflammation, and cardiovascular disease.
    9-PAHSA
  • HY-124873
    SERCA2a activator 1 2139330-34-8 99.71%
    SERCA2a activator 1 (Compound A) is a sarco/endoplasmic reticulum Ca2+-dependent ATPase 2a (SERCA2a) activator. SERCA2a activator 1 attenuates phospholamban inhibition and enhances the systolic and diastolic functions of the heart. SERCA2a activator 1 can be used for heart failure.
    SERCA2a activator 1
  • HY-149120
    ASM-IN-1 2913151-46-7 98.65%
    ASM-IN-1 is a potent and orally active acid sphingomyelinase (ASM) inhibitor with an IC50 value of 1.5 µM. ASM-IN-1 reduces lipid plaques in the aortic arch and aorta and reduces plasma ceramide concentration and Ox-LDL levels. ASM-IN-1 shows antiatherosclerotic and anti-inflammatory activity.
    ASM-IN-1
  • HY-17495A
    Carteolol hydrochloride 51781-21-6 99.96%
    Carteolol hydrochloride (OPC-1085 hydrochloride) is a non-selective beta blocker used to treat glaucoma.
    Carteolol hydrochloride
  • HY-B0093A
    Benazepril hydrochloride 86541-74-4 99.96%
    Benazepril (CGS14824A) hydrochloride is an orally active angiotensin-converting enzyme (ACE) inhibitor to reduce angiotensin-II production. Benazepril hydrochloride inhibits oxidative stress and inhibits apoptosis by the PI3K/Akt signaling pathway. In addition, Benazepril hydrochloride improves diabetic nephropathy and decreases proteinuria. Benazepril hydrochloride can be used in the study of hypertension, heart failure and diabetic nephropathy.
    Benazepril hydrochloride
  • HY-B1092A
    Gluconate sodium 527-07-1 ≥98.0%
    Gluconate sodium (D-Gluconic acid sodium salt) is an orally active glucose derivative. Gluconate sodium reduces nitric oxide and inflammatory cytokines (IL-1β and IL-6). Gluconate sodium inhibits ERK phosphorylation. Gluconate sodium has antioxidant and antiplatelet activation activities. Gluconate sodium has antitumor activity against colorectal cancer. Gluconate sodium improves osteoarthritis, intestinal damage and acute lung injury.
    Gluconate sodium
  • HY-N7071A
    Maduramicin ammonium 84878-61-5 ≥98.0%
    Maduramicin ammonium (Maduramycin ammonium) is isolated from the actinomycete Actinomadura rubra. Maduramicin ammonium (Maduramycin ammonium) is an anticoccidial agent for the the treatment of Eimeria spp., E. adenoeides, E. gallopavonis, and E. dispersa infection. Maduramicin ammonium (Maduramycin ammonium) induces cell apoptosis in chicken myocardial cells via intrinsic and extrinsic pathways.
    Maduramicin ammonium
  • HY-101355B
    CGP 20712 A 105737-62-0 ≥99.0%
    CGP 20712 A (CGP 20712 mesylate) is a highly selective β1-adrenoceptor antagonist with an IC50 of 0.7 nM. CGP 20712 A exhibits ~10,000-fold selectivity over β2-adrenoceptors.
    CGP 20712 A
  • HY-W006405
    Isoflavone 574-12-9
    Isoflavone is an orally available bioactive component of soy phytoestrogen with lipid-lowering and antioxidant activities. Isoflavone prevents a variety of chronic diseases by regulating fatty acid oxidation in the liver and gene expression in adipose tissue. In addition, isoflavone has important value in the research of cancer and cardiovascular diseases.
    Isoflavone
  • HY-W012814
    4-Methylcatechol 452-86-8 ≥98.0%
    4-Methylcatechol is an intermediate in the degradation of some alkylbenzenes and an orally active suicide inhibitor of catechol 2,3-dioxygenase (C23O). 4-Methylcatechol induces apoptosis in melanoma cells through oxidative stress, but some studies have also shown that 4-Methylcatechol is carcinogenic. In addition, 4-Methylcatechol has antiplatelet and blood pressure-lowering activities. 4-Methylcatechol can also inhibit protein oxidation in beef but does not disulfide formation.
    4-Methylcatechol
  • HY-W015007
    Metyrosine 672-87-7 ≥98.0%
    Metyrosine is a selective tyrosine hydroxylase enzyme inhibitor. Metyrosine exerts anti-inflammatory and anti-ulcerative effects. Metyrosine significantly inhibits high COX-2 activity. Metyrosine is a very effective agent for blood pressure control.
    Metyrosine
  • HY-W018723
    4-Aminobenzamidine dihydrochloride 2498-50-2 ≥98.0%
    4-Aminobenzamidine (p-Aminobenzamidine) dihydrochloride is a strong trypsin inhibitor. 4-Aminobenzamidine dihydrochloride acts as an orally active urokinase type plasminogen activator (uPA) inhibitor (Ki=82 μM). 4-Aminobenzamidine dihydrochloride can be used for cardiovascular diseases and anti-tumor study.
    4-Aminobenzamidine dihydrochloride
  • HY-N0830BS1
    Palmitic acid-13C16 sodium 2483736-17-8 ≥98.0%
    Palmitic acid-13C16 sodium is the 13C-labeled Palmitic acid sodium. Palmitic acid sodium is a long-chain saturated fatty acid commonly found in both animals and plants. Palmitic acid sodium can induce the expression of glucose-regulated protein 78 (GRP78) and CCAAT/enhancer binding protein homologous protein (CHOP) in in mouse granulosa cells.
    Palmitic acid-13C16 sodium
  • HY-N7564
    Methylliberine 51168-26-4 99.94%
    Methylliberine is a purine alkaloid metabolite of caffeine with oral activity.
    Methylliberine
  • HY-10264B
    Edoxaban tosylate monohydrate 1229194-11-9 99.97%
    Edoxaban (DU-176b) monohydrate is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Kis of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban monohydrate exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban monohydrate can be used for preventing thromboembolic disease research.
    Edoxaban tosylate monohydrate
  • HY-13911
    Hydroxyfasudil 105628-72-6 98.78%
    Hydroxyfasudil is a ROCK inhibitor, with IC50s of 0.73 and 0.72 μM for ROCK1 and ROCK2, respectively.
    Hydroxyfasudil
  • HY-15948
    Kif15-IN-1 672926-32-8 99.63%
    Kif15-IN-1 is an inhibitor of the mitotic Kinesin family member 15 (Kif15), and is used for the research of cellular proliferative diseases.
    Kif15-IN-1
  • HY-B0331
    Enalapril 75847-73-3 99.96%
    Enalapril (MK-421) is an angiotensin-converting enzyme (ACE) inhibitor, can be used for hypertensive diseases research.
    Enalapril
  • HY-100186
    GSK-2881078 1539314-06-1 99.74%
    GSK-2881078 is an orally active and nonsteroidal selective androgen receptor modulator (SARM) which act as partial AR agonists in androgenic tissues while mainly as complete AR agonists in synthetic metabolic tissues,induces AR-mediated transcriptional activation in PC3(AR)2 cells (EC50 = 3.99 nM) and the effect can be inhibited by the non-steroidal AR antagonist Bicalutamide. GSK-2881078 can be used in research of muscle weakness and cachexia associated with both chronic and acute illness.
    GSK-2881078
Cat. No. Product Name / Synonyms Application Reactivity